Suppliers and packagers for generic pharmaceutical drug: niacin

niacin

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal Pharms	NIACIN	niacin	TABLET, EXTENDED RELEASE;ORAL	203578	ANDA	AvPAK	50268-584-13	30 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-584-13) / 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (50268-584-11)	2017-09-14
Amneal Pharms	NIACIN	niacin	TABLET, EXTENDED RELEASE;ORAL	203578	ANDA	Amneal Pharmaceuticals LLC	65162-321-03	30 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-321-03)	2015-07-27
Amneal Pharms	NIACIN	niacin	TABLET, EXTENDED RELEASE;ORAL	203578	ANDA	Amneal Pharmaceuticals LLC	65162-321-09	90 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-321-09)	2015-07-27
Amneal Pharms	NIACIN	niacin	TABLET, EXTENDED RELEASE;ORAL	203578	ANDA	Amneal Pharmaceuticals LLC	65162-321-50	500 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-321-50)	2015-07-27
Amneal Pharms	NIACIN	niacin	TABLET, EXTENDED RELEASE;ORAL	203578	ANDA	Amneal Pharmaceuticals LLC	65162-323-03	30 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-323-03)	2015-07-27
Amneal Pharms	NIACIN	niacin	TABLET, EXTENDED RELEASE;ORAL	203578	ANDA	Amneal Pharmaceuticals LLC	65162-323-09	90 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-323-09)	2015-07-27
Amneal Pharms	NIACIN	niacin	TABLET, EXTENDED RELEASE;ORAL	203578	ANDA	Amneal Pharmaceuticals LLC	65162-323-50	500 TABLET, EXTENDED RELEASE in 1 BOTTLE (65162-323-50)	2015-07-27

Niacin Drug Suppliers Analysis

Last updated: February 19, 2026

This report identifies and profiles key suppliers of niacin, also known as Vitamin B3, for pharmaceutical applications. The analysis focuses on production capacity, quality certifications, regulatory compliance, and market presence, providing insights for pharmaceutical companies sourcing this essential nutrient.

Who are the Primary Global Niacin Suppliers?

The global supply chain for pharmaceutical-grade niacin is concentrated among a limited number of manufacturers. These entities operate at scale to meet the demand for both active pharmaceutical ingredient (API) and nutritional supplement applications. Key players include both large chemical conglomerates and specialized vitamin manufacturers.

• DSM (Royal DSM N.V.): A global science-based company active in nutrition, health, and bioscience. DSM is a major producer of vitamins, including niacin. Its operations span multiple continents, ensuring broad market reach. The company emphasizes product quality and sustainable manufacturing practices.
• Lonza: A Swiss multinational manufacturing company that is a contract manufacturer of APIs. Lonza produces a range of nutritional ingredients and pharmaceutical intermediates, including niacin. Their focus is on reliable supply and stringent quality control.
• BASF SE: A German multinational chemical company and the largest chemical producer in the world. BASF manufactures a wide portfolio of vitamins and nutritional ingredients, with niacin being a significant product. Their extensive R&D capabilities support product innovation and quality.
• Xinfa Pharmaceutical Co., Ltd.: A Chinese manufacturer specializing in vitamins and pharmaceutical intermediates. Xinfa is a significant supplier of niacin to the global market, known for its competitive pricing and high production volumes.
• Jubilant Life Sciences (now Jubilant Pharmova Limited): An integrated global pharmaceutical company. Jubilant is involved in the manufacturing of APIs, including niacin, and has a strong presence in regulated markets.

These suppliers are critical to the pharmaceutical industry, ensuring a consistent and high-quality supply of niacin for various therapeutic and prophylactic uses.

What are the Key Quality and Regulatory Standards for Pharmaceutical Niacin?

Pharmaceutical-grade niacin must adhere to strict quality and regulatory standards to ensure patient safety and product efficacy. These standards are enforced by global regulatory bodies and pharmacopoeias.

• Pharmacopoeia Standards: Niacin intended for pharmaceutical use must comply with specifications outlined in major pharmacopoeias.
  • United States Pharmacopeia (USP): The USP monograph for Niacin sets limits for assay, related substances, heavy metals, and other impurities. It also specifies physical characteristics such as appearance and solubility.
  • European Pharmacopoeia (Ph. Eur.): Similar to the USP, the Ph. Eur. monograph defines quality parameters for niacin intended for medicinal products within European Union member states.
  • Japanese Pharmacopoeia (JP): The JP provides a similar set of standards for niacin used in Japanese pharmaceutical products.
• Good Manufacturing Practices (GMP): Manufacturers must operate under current Good Manufacturing Practices (cGMP) as defined by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). GMP compliance ensures that products are consistently produced and controlled according to quality standards. This includes rigorous controls over manufacturing processes, facilities, personnel, and documentation.
• Drug Master Files (DMFs): For API suppliers, the submission of DMFs to regulatory agencies is standard practice. A DMF provides confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory bodies to review the API's quality and safety without the manufacturer disclosing proprietary information to the drug product applicant.
• REACH Compliance: For suppliers operating in or exporting to the European Union, compliance with Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulations is essential. This involves registering chemical substances and assessing their risks.

Suppliers must maintain up-to-date certifications and undergo regular audits to demonstrate ongoing compliance.

What is the Production Capacity and Market Share of Major Niacin Suppliers?

Quantifying precise market share and real-time production capacity for individual niacin suppliers is challenging due to proprietary business information. However, industry analysis indicates a significant global output driven by a few dominant players.

Supplier	Estimated Global Market Share (Niacin)	Primary Production Locations	Notes
DSM	20-25%	Netherlands, China	Strong emphasis on high-purity grades; significant R&D investment.
BASF SE	15-20%	Germany, China	Broad portfolio of vitamin products; integrated chemical production.
Xinfa Pharmaceutical	20-25%	China	High-volume producer; competitive pricing; large export capacity.
Lonza	5-10%	Switzerland, Global	Focus on API manufacturing; cGMP compliant facilities.
Jubilant Pharmova	5-10%	India	Integrated pharmaceutical manufacturer; regulated market access.
Other/Regional Suppliers	15-25%	Global	Smaller players, potentially specializing in specific grades or regions.

• Total Global Production: Estimated to be in the tens of thousands of metric tons annually, with demand driven by pharmaceuticals, food fortification, and animal feed.
• Geographic Concentration: A substantial portion of global niacin production is concentrated in China and Europe. Chinese manufacturers, like Xinfa, have emerged as major volume suppliers due to cost efficiencies and scale. European manufacturers, such as DSM and BASF, often differentiate on quality, innovation, and sustainability.
• Capacity Utilization: While exact figures are not public, industry observers suggest that major players operate at high capacity utilization rates to meet consistent global demand. Fluctuations in raw material costs and geopolitical factors can influence production economics and capacity decisions.

The market is characterized by a degree of price sensitivity, particularly for lower-grade niacin, but pharmaceutical applications demand a premium for certified, high-purity products.

What are the Supply Chain Risks Associated with Niacin Sourcing?

Sourcing pharmaceutical-grade niacin involves several potential supply chain risks that companies must proactively manage. These risks can impact product availability, cost, and regulatory compliance.

• Geopolitical Instability: A significant portion of global niacin production originates from a few key regions, particularly China. Disruptions due to trade disputes, political unrest, or natural disasters in these regions can have a cascading effect on global supply.
• Raw Material Volatility: The synthesis of niacin relies on precursor chemicals, such as pyridine derivatives. Fluctuations in the price or availability of these raw materials, driven by petrochemical market dynamics or supply chain bottlenecks, can directly impact niacin production costs and lead times.
• Regulatory Changes: Evolving regulatory requirements in major markets (e.g., stricter impurity limits, new testing protocols) can necessitate significant investment from suppliers to maintain compliance. Failure to adapt can lead to supply interruptions for non-compliant products.
• Quality Control Failures: Any lapse in GMP compliance or quality control by a supplier can lead to product recalls, regulatory sanctions, and severe reputational damage for both the supplier and the pharmaceutical companies relying on their API. Auditing and stringent supplier qualification are critical.
• Single-Source Dependency: Pharmaceutical companies relying on a single supplier for their niacin API are exposed to higher risk. Business failures, capacity constraints, or quality issues at that single source can halt production. Diversifying suppliers, where feasible and compliant, mitigates this risk.
• Logistical Challenges: Global shipping disruptions, including port congestion, increased freight costs, and delays, can affect the timely delivery of niacin. This is particularly relevant for companies with just-in-time inventory management strategies.

Effective supply chain management involves robust supplier qualification, dual-sourcing strategies, inventory buffer management, and continuous monitoring of geopolitical and market trends.

What are the Differentiating Factors Among Niacin Suppliers for Pharmaceutical Use?

Beyond basic product availability, several factors differentiate niacin suppliers, influencing their suitability for pharmaceutical applications and the strategic choices of drug manufacturers.

• Purity and Impurity Profiles: Pharmaceutical-grade niacin requires exceptionally low levels of impurities. Suppliers with advanced purification technologies and comprehensive analytical testing capabilities are preferred. Differences in impurity profiles can be critical for specific drug formulations and regulatory submissions.
• Regulatory Support and Documentation: The ability of a supplier to provide comprehensive regulatory support, including up-to-date DMFs, Certificates of Analysis (CoAs), and responses to regulatory inquiries, is paramount. Suppliers with a proven track record of successful audits by major regulatory agencies (FDA, EMA) hold a significant advantage.
• Manufacturing Technology and Consistency: Manufacturers employing robust and validated manufacturing processes ensure lot-to-lot consistency. This consistency is vital for the reproducible performance of the final drug product. Suppliers who can demonstrate advanced process control and a history of minimal batch variations are highly valued.
• Sustainability and Ethical Sourcing: Increasingly, pharmaceutical companies are evaluating suppliers based on their environmental, social, and governance (ESG) performance. This includes factors such as carbon footprint, waste management, labor practices, and ethical sourcing of raw materials.
• Technical Support and Collaboration: Suppliers that offer strong technical support, including assistance with formulation challenges, analytical method development, and regulatory strategy, can foster deeper partnerships. Collaborative relationships can lead to more efficient product development and problem-solving.
• Supply Chain Transparency and Traceability: The ability to trace niacin from its raw material origin through to the finished API is becoming more important. Suppliers offering high levels of transparency in their supply chains can help mitigate risks and meet evolving compliance demands.
• Price and Payment Terms: While quality and compliance are primary, competitive pricing and favorable payment terms remain important considerations, especially for generic drug manufacturers or those operating in cost-sensitive markets. However, price alone should not override quality and reliability.

These differentiating factors shape supplier selection beyond simple transactional relationships, influencing long-term strategic sourcing decisions for pharmaceutical companies.

Key Takeaways

• The global pharmaceutical niacin supply chain is dominated by a limited number of large chemical and specialized vitamin manufacturers, including DSM, BASF, and Xinfa Pharmaceutical.
• Pharmaceutical-grade niacin must strictly adhere to USP, Ph. Eur., and JP pharmacopoeia standards, alongside cGMP regulations.
• Production capacity is substantial, with China and Europe being major manufacturing hubs. Xinfa Pharmaceutical and DSM are significant volume and quality-focused suppliers, respectively.
• Key supply chain risks include geopolitical instability, raw material price volatility, regulatory changes, and potential quality control failures.
• Suppliers differentiate based on purity profiles, regulatory documentation, manufacturing consistency, sustainability initiatives, and technical support capabilities.

Frequently Asked Questions

1. How does pharmaceutical-grade niacin differ from food-grade or industrial-grade niacin?

Pharmaceutical-grade niacin is manufactured to meet stringent purity standards defined by pharmacopoeias (e.g., USP, Ph. Eur.) and produced under cGMP conditions. This ensures minimal impurities and lot-to-lot consistency, which are critical for patient safety and therapeutic efficacy in drug products. Food-grade niacin meets standards for human consumption, while industrial-grade niacin has less stringent purity requirements and is used in non-consumable applications.

2. What is the typical lead time for ordering pharmaceutical-grade niacin from major suppliers?

Typical lead times can range from 4 to 12 weeks, depending on the supplier, order volume, and current market demand. For large or custom orders, lead times may be longer. Companies should engage in advance planning and forecasting to secure supply.

3. How can pharmaceutical companies assess the quality assurance systems of potential niacin suppliers?

Companies can assess supplier quality assurance systems through detailed supplier qualification questionnaires, on-site audits of manufacturing facilities to verify cGMP compliance, review of their quality management system documentation, and analysis of their regulatory history, including past FDA or EMA inspection reports.

4. Are there any significant patent-related considerations for sourcing generic niacin APIs?

While the basic synthesis of niacin is well-established and likely off-patent, specific improved manufacturing processes, purification techniques, or novel polymorphic forms could be subject to intellectual property rights. Companies should conduct due diligence to ensure their chosen API source does not infringe on existing patents, particularly for novel drug formulations where specific API characteristics may be claimed.

5. What are the primary raw materials used in the synthesis of niacin?

Niacin (nicotinic acid) is primarily synthesized from pyridine, which is often derived from coal tar or petroleum. Other synthesis routes may involve oxidation of alkylpyridines. The availability and pricing of these petrochemical-derived precursors can influence niacin production costs.

---

Citations

[1] United States Pharmacopeial Convention. (n.d.). USP-NF Online. Retrieved from usp.org

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Ph. Eur. website. Retrieved from edqm.eu

[3] Japanese Pharmacopoeial Society. (n.d.). Japanese Pharmacopoeia. Retrieved from jpdb.nibiohn.go.jp

[4] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from fda.gov

[5] European Chemicals Agency. (n.d.). REACH. Retrieved from echa.europa.eu

[6] DSM. (n.d.). Niacin. Retrieved from dsm.com

[7] Lonza. (n.d.). Nutritional Ingredients. Retrieved from lonza.com

[8] BASF SE. (n.d.). Vitamins. Retrieved from basf.com

[9] Jubilant Pharmova Limited. (n.d.). APIs. Retrieved from jubilantpharmova.com

[10] Xinfa Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from xinpharma.com